Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Human corticotropin-releasing factor (hCRF) is a potent respiratory analeptic

Physiological and clinical aspects

  • 13 Accesses

  • 1 Citations

Summary

During intravenous corticotropin-releasing factor stimulation tests we observed a deepening of the tidal volume in 35 patients. To investigate this presumed respiratory stimulation we measured respiratory parameters in 12 healthy male volunteers in a single-blind placebo-controlled trial. The intravenous 60-s infusion of 100 µg of human corticotropin-releasing factor induced a very potent respiratory stimulation in every subject: respiratory minute volume (mean ± S.D.) increased by 81% from 6.319±0.577 to 11.464±1.264 liters per min (P<0.001), whereas there was only a slight rise in the mean respiratory rate from 12.4±3.0 to 14.7±2.7 breaths per min (P<0.001). Mean tidal volume increased from 531±105 to 809±175 ml (P<0.001). Mean end-tidal partial pressure of carbon dioxide decreased (P<0.001) from 40.3±1.2 to 33.4±1.2 mmHg, whereas mean end-tidal partial pressure of oxygen increased (P<0.001) from 93.2±5.4 to 113.5±5.4 mmHg. After 10 to 20 min both end-tidal carbon dioxide and oxygen partial pressures returned to the baseline values. The placebo had no measurable effects.

We conclude that human corticotropin-releasing factor is a potent respiratory stimulant. With 100 µg the resting respiratory minute volume increases by 81%. These data point to the possible importance of the corticotropin-releasing factor as a useful adjunct in the management of patients with alveolar hypoventilation.

This is a preview of subscription content, log in to check access.

Abbreviations

hCRF:

human corticotropin-releasing factor

PETCO2 :

end-tidal partial pressure of carbon dioxide (the last portion of the VT during expiration, called end-tidal volume, contains CO2 from the alveolar region)

PETO2 :

end-tidal partial pressure of oxygen

\(\dot V_E \) :

minute volume

VT :

respiratory tidal volume

References

  1. 1.

    Bailar JC, Louis TA, Lavori PW, Polansky M (1984) A classification for biomedical research reports. N Engl J Med 311:1482–1487

  2. 2.

    Böhmer G, Schmid K, Oppermann D, Ramsbott M (1985) Effects of human corticotropin-releasing factor on central respiratory activity in the rabbit. Pflügers Arch Suppl 405:48 (Abstract)

  3. 3.

    Chrousos GP, Schulte HM, Oldfield EH, Gold PH, Cutler GB, Loriaux DL (1984) The corticotropin-releasing factor stimulation test. N Engl J Med 310:622–626

  4. 4.

    Cohen MJ (1979) Neurogenesis of respiratory rhythm in the mammal. Physiol Rev 59:1105–1173

  5. 5.

    Coté J, Lefèvre G, Labrie F, Barden N (1983) Distribution of corticotropin-releasing factor in bovine brain determined by radioimmunoassay. Regul Pept 5:189–195

  6. 6.

    Edwards G, Leszczynski SO (1967) A double-blind trial of five respiratory stimulants in patients in acute ventilatory failure. Lancet II:226–229

  7. 7.

    Elashoff JD (1981) Down with multiplet-tests. Gastroenterology 80:615–619

  8. 8.

    Fischman AJ, Moldow RL (1982) Distribution of CRF-like immunoreactivity in the rabbit. Peptides 3:841–844

  9. 9.

    Grossman A, Nieuwenhuyzen-Kruseman AC, Perry L, Tomlin S, Schally AV, Coy DH, Rees LH, Comaru-Schally AM, Besser GM (1982) New hypothalamic hormone, corticotropin-releasing factor, specifically stimulates the release of adrenocorticotropic hormone and cortisol in man. Lancet I:921–922

  10. 10.

    Hermus A, Pieters G, Pesman G, Buys W, Smals A, Benraad T, Kloppenborg P (1984) Differential effects of ovine and human corticotrophin-releasing factor in human subjects. Clin Endocrinol (Oxf) 21:589–595

  11. 11.

    Hirsh K, Wang SC (1974) Selective respiratory stimulation action of doxapram compared to pentylenetetrazol. J Pharmacol Exp Ther 189:1–4

  12. 12.

    Little GM (1962) Use of amiphenazole in respiratory failure. Br Med J 1:223–226

  13. 13.

    Louis TA, Lavori PW, Bailar JC, Polansky M (1984) Cross-over and self-controlled designs in clinical research. N Engl J Med 310:24–31

  14. 14.

    Lytras N, Grossman A, Perry L, Tomlin S, Wass JAH, Coy DH, Schally AV, Rees LH, Besser GM (1984) Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf) 20:71–84

  15. 15.

    Miller MJ, Fiedler HT (1965) Pharmacologic effects of doxapram in the awake human. J Am Geriatr Soc 13 (2):160–165

  16. 16.

    Moser KM, Luchsinger PC, Adamson JS, McMahon SM, Schlueter DP, Spivack M, Weg JG (1973) Respiratory stimulation with intravenous doxapram in respiratory failure. N Engl J Med 288:427–431

  17. 17.

    Müller OA, Stalla GK, von Werder K (1983) Corticotropin releasing factor: a new tool for the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 57:227–229

  18. 18.

    Olschowka JA, O'Donohue TL, Mueller GP, Jacobowitz DM (1982) Hypothalamic and extrahypothalamic distribution of CRF-like immunoreactive neurons in the rat brain. Neuroendocrinology 35:305–308

  19. 19.

    Orth DN, Jackson RV, De Cherney GS, DeBold CR, Alexander AN, Island DP, Rivier J, Rivier C, Spiess J, Vale W (1983) Effect of synthetic ovine corticotropin-releasing factor. J Clin Invest 71:587–595

  20. 20.

    Rees LH (1984) Recent advances in the diagnosis and treatment of pituitary disease. In: Labrie F, Proulx L (eds) Endocrinology. Excerpta Medica (International Congress Series 655), Amsterdam, pp 11–17

  21. 21.

    Shibahara S, Morimoto Y, Furutani Y, Notake M, Takahashi H, Shimizu S, Horikawa S, Numa S (1983) Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. EMBO J 2:775–779

  22. 22.

    Steele AD, Rodman T (1966) The effect of a new analeptic agent on arterial blood gases and minute ventilation in adult males. Am Rev Respir Dis 94:600–607

  23. 23.

    Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213:1394–1397

  24. 24.

    Wilkin JK (1981) Flushing reactions: consequences and mechanisms. Ann Intern Med 95:468–476

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Oppermann, D., Huber, I., Nink, M. et al. Human corticotropin-releasing factor (hCRF) is a potent respiratory analeptic. Klin Wochenschr 64, 924–928 (1986). https://doi.org/10.1007/BF01728617

Download citation

Key words

  • Human corticotropin-releasing factor (hCRF)
  • Biological activity
  • Respiratory analeptic
  • Human beings
  • Hyperventilation